Dabur's '3x immunity' Chyawanprash claim upheld as unsubstantiated — twice

In February 2013, ASCI's Consumer Complaints Council upheld a complaint against Dabur India's print ad for Chyawanprash. The ad claimed the product 'provides 3 times more immunity', 'helps improve the ability to fight illness by 3 times', and that 'ONLY Dabur Chyawanprash provides immunity'. The advertiser could not substantiate the claims with support data; the ad contravened Chapter I.4 of the ASCI code and the complaint was upheld.

Two years later, the claim came back. In April 2015 ASCI published its February 2015 review, and a complaint against Dabur was again upheld: the Chyawanprash ad claimed 'three times more immunity' that 'makes kids strong from within' and raises the ability to fight illness by three times — claims ASCI found unsubstantiated.

ASCI is self-regulatory, so neither ruling carried a monetary penalty; the expectation is that the offending creative is modified or withdrawn. The repeat mattered because Chyawanprash was one of Dabur's flagship ayurvedic products, marketed to parents on immunity and strength, and the second upheld ruling showed the same evidence gap surfacing in a new campaign cycle.

No fine (self-regulation), but the same claim was upheld twice in two years and the ads had to be modified or withdrawn; Dabur could not substantiate it with data.

The '3 times more immunity' benefit was a numerical health claim with no substantiation data behind it.

Re-running the same unsubstantiated claim two years later produced a second upheld ruling instead of a fixed claim.

Immunity and 'strong from within' wording aimed at parents made the claim both powerful and high-risk.

Self-regulation costs nothing in fines, but two upheld rulings on the same claim erode trust in the brand and the category.

A health claim rejected once doesn't expire with the campaign: re-running the same unsubstantiated benefit in new creative courts the same upheld ruling — and a second public record of the failure.

After the 2015 ruling, Dabur's Chyawanprash marketing moved away from the '3 times' framing, but immunity claims around ayurvedic products kept drawing regulator attention across the industry. The two upheld rulings became standard references in ASCI's health-claim decisions — the case agencies cite when a client insists a product benefit 'has always been said this way'. Repetition is not substantiation.